87 related articles for article (PubMed ID: 15829299)
61. Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions.
Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
Front Immunol; 2022; 13():1091668. PubMed ID: 36483568
[TBL] [Abstract][Full Text] [Related]
62. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
[TBL] [Abstract][Full Text] [Related]
63. Molecular decoys: antidotes, therapeutics and immunomodulators.
Gershoni JM
Curr Opin Biotechnol; 2008 Dec; 19(6):644-51. PubMed ID: 18977299
[TBL] [Abstract][Full Text] [Related]
64. Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.
Raska M; Moldoveanu Z; Novak J; Hel Z; Novak L; Bozja J; Compans RW; Yang C; Mestecky J
Vaccine; 2008 Mar; 26(12):1541-51. PubMed ID: 18304708
[TBL] [Abstract][Full Text] [Related]
65. Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein.
Meyuhas R; Noy H; Fishman S; Margalit A; Montefiori DC; Gross G
Biochem Biophys Res Commun; 2009 Aug; 386(2):402-6. PubMed ID: 19538939
[TBL] [Abstract][Full Text] [Related]
66. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
67. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
Xiang SH; Doka N; Choudhary RK; Sodroski J; Robinson JE
AIDS Res Hum Retroviruses; 2002 Nov; 18(16):1207-17. PubMed ID: 12487827
[TBL] [Abstract][Full Text] [Related]
68. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
69. HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1.
Meyuhas R; Noy H; Montefiori DC; Denisova G; Gershoni JM; Gross G
Mol Immunol; 2005 May; 42(9):1099-109. PubMed ID: 15829299
[TBL] [Abstract][Full Text] [Related]
70. Janusin: new molecular design for bispecific reagents.
Traunecker A; Lanzavecchia A; Karjalainen K
Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404
[TBL] [Abstract][Full Text] [Related]
71. [Analysis of the principal neutralization site of HIV-1 and vaccine research].
Okamoto Y; Honda M
Tanpakushitsu Kakusan Koso; 1997 May; 42(7 Suppl):1201-8. PubMed ID: 9170954
[No Abstract] [Full Text] [Related]
72. CD4 immunoadhesins in anti-HIV therapy: new developments.
Chamow SM; Duliege AM; Ammann A; Kahn JO; Allen JD; Eichberg JW; Byrn RA; Capon DJ; Ward RH; Ashkenazi A
Int J Cancer Suppl; 1992; 7():69-72. PubMed ID: 1428410
[TBL] [Abstract][Full Text] [Related]
73.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
74.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
